Keywords: repligen, rg1068, fails, autism, trial, usa-based, synthetic

Repligen's RG1068 fails in autism trial

Article | 05 January 2004

Print This

USA-based Repligen's RG1068, a synthetic human secretin, has failed to meet its primary goals in a Phase III trial for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in